Hypertrophic Cardiomyopathy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Tenaya Therapeutics, Shandong Suncadia Medicine, MyoKardia

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypertrophic Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypertrophic Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hypertrophic Cardiomyopathy Pipeline Insight, 2026 [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertrophic Cardiomyopathy Market.

The Hypertrophic Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hypertrophic Cardiomyopathy Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Hypertrophic Cardiomyopathy treatment therapies with a considerable amount of success over the years.

*
Hypertrophic Cardiomyopathy companies working in the treatment market are Tenaya Therapeutics, Shandong Suncadia Medicine, MyoKardia, Imbria Pharmaceuticals, Cytokinetics, Bristol-Myers Squibb, Edgewise Therapeutics, Inc., Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, and others, are developing therapies for the Hypertrophic Cardiomyopathy treatment

*
Emerging Hypertrophic Cardiomyopathy therapies in the different phases of clinical trials are- TN 201, HRS 1893, MYK-224, Ninerafaxstat, Ficamten, Mavacamten, EDG-7500, Aficamten, RP-A501, IMB-1018972, and others are expected to have a significant impact on the Hypertrophic Cardiomyopathy market in the coming years.

*
In April 2025, Bristol Myers Squibb's (BMS) Phase III ODYSSEY-HCM trial testing Camzyos (mavacamten) in non-obstructive hypertrophic cardiomyopathy (nHCM) patients did not meet its two primary endpoints. After 48 weeks of treatment, the cardiac myosin inhibitor failed to show a meaningful benefit over placebo in enhancing either the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-23 CSS) or peak oxygen consumption (pVO2). The study, which was randomized, double-blind, and placebo-controlled, enrolled 580 adults with symptomatic nHCM categorized as NYHA class II or III.

*
In April 2025, Interim findings from the Phase Ib/2 MYPEAK-1 trial (NCT05836259) revealed that three patients with severe heart disease showed improved physical activity after receiving a single dose of Tenaya Therapeutics' gene therapy, TN-201. Presented at a late-breaking session during the 2025 American College of Cardiology (ACC) conference, the data indicated that TN-201, designed to treat hypertrophic cardiomyopathy (HCM), was well tolerated and demonstrated a favorable safety profile in the initial three patients enrolled in the first cohort.

*
In September 2024, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company focused on muscle diseases, has announced top-line data for EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). EDG-7500 is an innovative oral, selective cardiac sarcomere modulator designed to reduce early contraction velocity and improve impaired cardiac relaxation associated with HCM.

Hypertrophic Cardiomyopathy Overview

Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disorder characterized by abnormal thickening (hypertrophy) of the heart muscle, particularly the myocardium the muscle of the heart's main pumping chamber, the left ventricle. This thickening makes it harder for the heart to pump blood effectively.

Get a Free Sample PDF Report to know more about Hypertrophic Cardiomyopathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-pipeline-insight [https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Hypertrophic Cardiomyopathy Drugs Under Different Phases of Clinical Development Include:

*
TN 201: Tenaya Therapeutics

*
HRS 1893: Shandong Suncadia Medicine

*
MYK-224: MyoKardia

*
Ninerafaxstat: Imbria Pharmaceuticals

*
Ficamten: Cytokinetics

*
Mavacamten: Bristol-Myers Squibb

*
EDG-7500: Edgewise Therapeutics, Inc.

*
Aficamten: Ji Xing Pharmaceuticals

*
RP-A501: Rocket Pharmaceuticals

*
IMB-1018972: Imbria Pharmaceuticals

Hypertrophic Cardiomyopathy Route of Administration

Hypertrophic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Hypertrophic Cardiomyopathy Molecule Type

Hypertrophic Cardiomyopathy Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Hypertrophic Cardiomyopathy Pipeline Therapeutics Assessment

*
Hypertrophic Cardiomyopathy Assessment by Product Type

*
Hypertrophic Cardiomyopathy By Stage and Product Type

*
Hypertrophic Cardiomyopathy Assessment by Route of Administration

*
Hypertrophic Cardiomyopathy By Stage and Route of Administration

*
Hypertrophic Cardiomyopathy Assessment by Molecule Type

*
Hypertrophic Cardiomyopathy by Stage and Molecule Type

DelveInsight's Hypertrophic Cardiomyopathy Report covers around 10+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Hypertrophic Cardiomyopathy product details are provided in the report. Download the Hypertrophic Cardiomyopathy pipeline report to learn more about the emerging Hypertrophic Cardiomyopathy therapies [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Hypertrophic Cardiomyopathy Therapeutics Market include:

Key companies developing therapies for Hypertrophic Cardiomyopathy are - Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Sanofi S.A., Astra Zeneca Plc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG, and others.

Hypertrophic Cardiomyopathy Pipeline Analysis:

The Hypertrophic Cardiomyopathy pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Hypertrophic Cardiomyopathy with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertrophic Cardiomyopathy Treatment.

*
Hypertrophic Cardiomyopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Hypertrophic Cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertrophic Cardiomyopathy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypertrophic Cardiomyopathy drugs and therapies [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypertrophic Cardiomyopathy Pipeline Market Drivers

*
The prevalence of hypertrophic cardiomyopathy (HCM) is increasing globally, growing demand for effective treatment options, increasing awareness of HCM are some of the important factors that are fueling the Hypertrophic Cardiomyopathy Market.

Hypertrophic Cardiomyopathy Pipeline Market Barriers

*
However, limited understanding of the disease, high cost of treatment, limited awareness of the disease and other factors are creating obstacles in the Hypertrophic Cardiomyopathy Market growth.

Scope of Hypertrophic Cardiomyopathy Pipeline Drug Insight

*
Coverage: Global

*
Key Hypertrophic Cardiomyopathy Companies: Tenaya Therapeutics, Shandong Suncadia Medicine, MyoKardia, Imbria Pharmaceuticals, Cytokinetics, Bristol-Myers Squibb, Edgewise Therapeutics, Inc., Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, and others

*
Key Hypertrophic Cardiomyopathy Therapies: TN 201, HRS 1893, MYK-224, Ninerafaxstat, Ficamten, Mavacamten, EDG-7500, Aficamten, RP-A501, IMB-1018972, and others

*
Hypertrophic Cardiomyopathy Therapeutic Assessment: Hypertrophic Cardiomyopathy current marketed and Hypertrophic Cardiomyopathy emerging therapies

*
Hypertrophic Cardiomyopathy Market Dynamics: Hypertrophic Cardiomyopathy market drivers and Hypertrophic Cardiomyopathy market barriers

Request for Sample PDF Report for Hypertrophic Cardiomyopathy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hypertrophic Cardiomyopathy Report Introduction

2. Hypertrophic Cardiomyopathy Executive Summary

3. Hypertrophic Cardiomyopathy Overview

4. Hypertrophic Cardiomyopathy- Analytical Perspective In-depth Commercial Assessment

5. Hypertrophic Cardiomyopathy Pipeline Therapeutics

6. Hypertrophic Cardiomyopathy Late Stage Products (Phase II/III)

7. Hypertrophic Cardiomyopathy Mid Stage Products (Phase II)

8. Hypertrophic Cardiomyopathy Early Stage Products (Phase I)

9. Hypertrophic Cardiomyopathy Preclinical Stage Products

10. Hypertrophic Cardiomyopathy Therapeutics Assessment

11. Hypertrophic Cardiomyopathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hypertrophic Cardiomyopathy Key Companies

14. Hypertrophic Cardiomyopathy Key Products

15. Hypertrophic Cardiomyopathy Unmet Needs

16 . Hypertrophic Cardiomyopathy Market Drivers and Barriers

17. Hypertrophic Cardiomyopathy Future Perspectives and Conclusion

18. Hypertrophic Cardiomyopathy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertrophic-cardiomyopathy-pipeline-2026-moa-and-roa-insights-clinical-trials-status-and-key-companies-involved-by-delveinsight-tenaya-therapeutics-shandong-suncadia-medicine-myokardia]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.